Potential DMD therapy MP1032 granted orphan drug status by FDA
MP1032, MetrioPharm’s oral therapy candidate for Duchenne muscular dystrophy (DMD), has been designated an orphan drug by the U.S. Food and Drug Administration (FDA). A Phase 2 trial testing MP1032 in DMD patients is expected to start next year. “Currently, DMD cannot be cured, but it can be treated,”…